Synonym
Dapoxetine Free Base; LY210448; LY-210448; LY 210448; (S)-(+)-Dapoxetine
IUPAC/Chemical Name
(S)-N,N-dimethyl-3-(naphthalen-1-yloxy)-1-phenylpropan-1-amine
InChi Key
USRHYDPUVLEVMC-FQEVSTJZSA-N
InChi Code
InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3/t20-/m0/s1
SMILES Code
O(CC[C@H](N(C)C)C1=CC=CC=C1)C=2C3=C(C=CC2)C=CC=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
to be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation.
In vitro activity:
The purpose of this study was to investigate the therapeutic efficacy of transdermal delivery of DH (Dapoxetine HCl) in transethosome nanovesicles (TENVs). The TENV formulations were assessed for entrapment efficiency (EE-%), vesicle size, zeta potential, in vitro DH release, and skin permeation. The release behavior of DH from DH-TENVs was investigated to confirm whether the DH-TENVs had the ability to release DH in a sustained manner. Rapid DH release from free DH solution in the dialysis bag was observed, with approximately 95% of the DH being released in the first 3 h (Figure S1A–C). In contrast, the DH in DH-TENVs demonstrated a slow and controlled release, with about 53–85% of the DH being released within 8 h (Table 2). The results indicate that DH-TENVs can improve transdermal delivery of DH and thereby alleviate RA.
Reference: Int J Nanomedicine. 2020; 15: 1517–1535. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065716/
In vivo activity:
The effects of 8-OH-DPAT and dapoxetine on the sexual behavior of male rats were investigated in this study. Dapoxetine significantly reduced the ejaculation performance at a dose of 60 mg/kg by delaying the latency of mounts and decreasing the latency of ejaculation and post-ejaculatory interval. Significant differences in the gene expression profiles were observed in the EJ (257 genes), DPAT (349 genes) and the DAP (207 genes) compared with the control rats In the present study, Drd4 was significantly upregulated (fold change: 2.42) following dapoxetine treatment whereas no such trend was noted regarding other 5-HT receptor or transporter genes.
Reference: Acta Pharm Sin B. 2017 May; 7(3): 381–389. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5430880/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
0.0 |
0.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
305.42
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Aldawsari HM, Badr-Eldin SM. Enhanced pharmacokinetic performance of dapoxetine hydrochloride via the formulation of instantly-dissolving buccal films with acidic pH modifier and hydrophilic cyclodextrin: Factorial analysis, in vitro and in vivo assessment. J Adv Res. 2020 May 1;24:281-290. doi: 10.1016/j.jare.2020.04.019. PMID: 32419956; PMCID: PMC7215178. 2. Salem HF, Nafady MM, Kharshoum RM, Abd El-Ghafar OA, Farouk HO. Mitigation of Rheumatic Arthritis in a Rat Model via Transdermal Delivery of Dapoxetine HCl Amalgamated as a Nanoplatform: In vitro and in vivo Assessment. Int J Nanomedicine. 2020 Mar 6;15:1517-1535. doi: 10.2147/IJN.S238709. PMID: 32189966; PMCID: PMC7065716.
3. Qin X, Ma X, Tu D, Luo Z, Huang J, Mo C. The effect of 8-OH-DPAT and dapoxetine on gene expression in the brain of male rats during ejaculation. Acta Pharm Sin B. 2017 May;7(3):381-389. doi: 10.1016/j.apsb.2016.11.004. Epub 2017 Mar 14. PMID: 28540176; PMCID: PMC5430880.
In vitro protocol:
1. Aldawsari HM, Badr-Eldin SM. Enhanced pharmacokinetic performance of dapoxetine hydrochloride via the formulation of instantly-dissolving buccal films with acidic pH modifier and hydrophilic cyclodextrin: Factorial analysis, in vitro and in vivo assessment. J Adv Res. 2020 May 1;24:281-290. doi: 10.1016/j.jare.2020.04.019. PMID: 32419956; PMCID: PMC7215178. 2. Salem HF, Nafady MM, Kharshoum RM, Abd El-Ghafar OA, Farouk HO. Mitigation of Rheumatic Arthritis in a Rat Model via Transdermal Delivery of Dapoxetine HCl Amalgamated as a Nanoplatform: In vitro and in vivo Assessment. Int J Nanomedicine. 2020 Mar 6;15:1517-1535. doi: 10.2147/IJN.S238709. PMID: 32189966; PMCID: PMC7065716.
In vivo protocol:
1. Aldawsari HM, Badr-Eldin SM. Enhanced pharmacokinetic performance of dapoxetine hydrochloride via the formulation of instantly-dissolving buccal films with acidic pH modifier and hydrophilic cyclodextrin: Factorial analysis, in vitro and in vivo assessment. J Adv Res. 2020 May 1;24:281-290. doi: 10.1016/j.jare.2020.04.019. PMID: 32419956; PMCID: PMC7215178. 2. Qin X, Ma X, Tu D, Luo Z, Huang J, Mo C. The effect of 8-OH-DPAT and dapoxetine on gene expression in the brain of male rats during ejaculation. Acta Pharm Sin B. 2017 May;7(3):381-389. doi: 10.1016/j.apsb.2016.11.004. Epub 2017 Mar 14. PMID: 28540176; PMCID: PMC5430880
1: Li J, Liu D, Wu J, Fan X, Dong Q. Dapoxetine for the treatment of premature ejaculation: a meta-analysis of randomized controlled trials with trial sequential analysis. Ann Saudi Med. 2018 Sep-Oct;38(5):366-375. doi: 10.5144/0256-4947.2018.366. PMID: 30284992; PMCID: PMC6180218.
2: Dapoxetine: LY 210448. Drugs R D. 2005;6(5):307-11. doi: 10.2165/00126839-200506050-00007. PMID: 16128601.
3: Zhao GJ, Guo Q, Li YF, Zhang YG. Efficacy and safety of dapoxetine for premature ejaculation: an updated systematic review and meta-analysis. Sex Health. 2019 Aug;16(4):301-313. doi: 10.1071/SH18005. PMID: 32172793.
4: McMahon CG. Dapoxetine for premature ejaculation. Expert Opin Pharmacother. 2010 Jul;11(10):1741-52. doi: 10.1517/14656566.2010.493174. PMID: 20540653.
5: Sangkum P, Badr R, Serefoglu EC, Hellstrom WJ. Dapoxetine and the treatment of premature ejaculation. Transl Androl Urol. 2013 Dec;2(4):301-11. doi: 10.3978/j.issn.2223-4683.2013.12.01. PMID: 26816743; PMCID: PMC4708110.
6: Hoy SM, Scott LJ. Dapoxetine: in premature ejaculation. Drugs. 2010 Jul 30;70(11):1433-43. doi: 10.2165/11204750-000000000-00000. PMID: 20614950.
7: Abu El-Hamd M, Abdelhamed A. Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial. Andrologia. 2018 Feb;50(1). doi: 10.1111/and.12829. Epub 2017 May 12. PMID: 28497478.
8: Wang YB, Mao Y, Wei Q, Wu TX, Dong Q. [Dapoxetine in treatment of premature ejaculation: a systematic review]. Beijing Da Xue Xue Bao Yi Xue Ban. 2010 Aug 18;42(4):425-32. Chinese. PMID: 20721257.
9: Dapoxetine for premature ejaculation. Drug Ther Bull. 2014 Mar;52(3):30-3. doi: 10.1136/dtb.2014.3.0240. PMID: 24627135.
10: Russo A, Capogrosso P, Ventimiglia E, La Croce G, Boeri L, Montorsi F, Salonia A. Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review. Int J Clin Pract. 2016 Sep;70(9):723-33. doi: 10.1111/ijcp.12843. Epub 2016 Jul 25. PMID: 27456527.
